European Journal of Molecular & Clinical Medicine (EJMCM)
ISSN: 2515-8260 Volume 07, Issue 08, 2020

**Review article**

# Recent updates on Cyclin-Dependent Kinase 8 for targeted cancer therapy

**Mr. Mangi Lal Choudhary[1], Dr. S.S. Sisodia[2]**

[1]Rasearch Scholar, Department of pharmacology, B.N. College of pharmacy, Udaipur, Rajasthan-313301

[2]Principal and Professor, HOD Department of pharmacology, B.N. College of pharmacy, Udaipur, Rajasthan-313301

***Corresponding author: Mr. Mangi Lal Choudhary,** Research Scholar, Department of pharmacology, B.N. College of pharmacy Udaipur, Rajasthan India: 313301

Email: ashokkumarchoudhary95@gmail.com, Cont. +91 9784455883




**ABSTRACT:** Cyclin-structured kinase 8 (CDK8) performs a essential function in regulating transcription both via its affiliation with the Mediator complicated or via way of means of phosphorylating transcription factors. Myriads of genetic and biochemical research have establishedCDK8 as a key oncogenic driving force in lots of cancers. Specifically, CDK8-mediated activation of oncogenic Wnt-β-catenin signaling, transcription of estrogen-inducible genes, and suppression of exceptional enhancer-related genes contributes to oncogenesis in colorectal, breast, and hematological malignancies, respectively. However, at the same time as maximum studies helps the function of CDK8 as an oncogene, different paintings has raised the opportunity of its opposite function. The various organic features of CDK8 and its apparently context-precise roles in distinct forms of cancers have spurred a fantastic quantity of hobby and possibly an excellent greater quantity of controversy withinside the improvement of CDK8 inhibitors as ability most cancers healing agents. Herein, we overview the ultra-modern panorama of CDK8 biology and its involvement in carcinogenesis. We dissect contemporary efforts in coming across CDK8inhibitors and try to offer an outlook on the destiny of CDK8-focused most cancers therapies.

**Keywords**: Cancer, Immune escape, Inflammation, Metastasis, Targeted therapy, CDK8.

## Introduction

Cancer is a ailment consisting of each genetic and epigenetic changes. The initiation and development of human stable tumors is related with accumulation of variations in the feature of key regulatory genes. Many unique factors, which includes modifications in genome reproduction variety and structure, can disrupt desirable gene functioning.[1] There is broad settlement that unique recurrent genomic aberrations may additionally embody genes that are essential for tumor development. However, the useful end result of recurrent abnormalities is no longer usually apparent, due to the fact a alternate in DNA replica quantity does no longer necessarily result in true modifications in expression.[2] Progression via the mobile division cycle is pushed via cyclins, which bind to and set off their catalytic partners, the cyclin-dependent kinases (CDKs). Specific heterodimeric cyclin–CDK complexes phosphorylate a plethora of mobile proteins to promote entry into and development thru the G1 section of the cellphone cycle, to force DNA synthesis (during S phase) and to set off segregation of the newly duplicated chromosomes to the daughter cells throughout mitosis, thereby making sure that the telephone cycle progresses in an ordered manner. The feature of these cyclin/Cdk pairs has been specially properly set up in the manipulate of the eukaryotic phone cycle the place a number of of these things to do set off the important transitions of the mobile cycle.[3] Mammalian cyclin and CDK households every comprise greater than 20 members, however solely a few cyclin–CDK complexes are recognized to immediately participate in the mobile division cycle. Cyclin-dependent kinases (Cdks) comprise a serine/threonine-specific catalytic core and they associate with regulatory subunits acknowledged as cyclins, which manage kinase pastime and substrate specificity.[4] Most Cdk household contributors additionally possess inhibitory (threonine 14, T14; tyrosine 15, Y15 in Cdk1) and activating (threonine 161, T161 in Cdk1) phosphorylation sites. Cyclin/Cdk pairs do no longer solely feature in the manager of the cellphone cycle; a developing range of research implicate Cdks in different cell processes. In yeast, the Pho8O-Pho85 cyclin-Cdk complicated is worried in a pathway that senses inorganic phosphate in the cell.[5] CDK8 and its carefully associated paralog CDK19 (80% identity) are transcription-regulating serine/threonine kinases that, in contrast to better-known contributors of the CDK household (such as CDK1, CDK2 or CDK4/6), do no longer mediate cellphone cycle progression.[6] CDK8 or CDK19, collectively with their binding companion Cyclin C and MED12 and MED13 proteins, structure the CDK module of transcriptional Mediator complex. Growth elements set off the expression of D-type cyclins (cyclins D1, D2 and D3), which are consequently considered as molecular hyperlinks between the mobile phone surroundings and the core mobile phone cycle machinery.[7] The involvement

of mobile cycle regulators in transcription has been a long-standing affair and one of the best-characterized examples stays intimately linked to phone cycle control: the Rb/E2F pathway. CDK8 is a nuclear serine-threonine kinase that features as a transcriptional regulator. Most of what is acknowledged about CDK8 outcomes from its facultative affiliation with the Mediator complex, however when you consider that solely a fraction of CDK8 is related with Mediator in cells, roles backyard of this complicated are additionally possible. CDK8 can phosphorylate Ser2 and Ser5 inside the CTD repeats in vitro,4-6,28,35 however its in vivo contributions continue to be unwell defined. Cdk7 (previously known as Mol5) and cyclin H, two subunits of a kinase complex in the past recognized as CAK (Cdk-activating kinase) had been proven to co-purify with different TFIIH subunits.




**Fig 1. Simplified schematic of the role of the Mediator complex and CDK8 in the initiation of transcription.**

*The preinitiation complex forms following binding of the Mediator complex, TFIID and other general transcription factors in a step-wise manner that eventually recruits RNA polymerase II, and finally TFIIH, to the complex. The helicase activity of TFIIH opens the DNA to initiate transcription, and CDK7 activity contributes to promoter escape by breaking interactions with some factors through phosphorylation of RNA polymerase II CTD Ser5, and also Ser7. The RNA polymerase transcribes around 20-100 bases downstream of the promoter before pausing and in another regulatory process, following recruitment of the CDK8 kinase and CDK9 activation, phosphorylation of CTD Ser2 and other substrates, that loses the remaining components of the initiation complex, yielding a fully functional elongation complex.*

CDK7 has been established to phosphorylate each Ser5 and Ser7 in vitro, however current chemical genetics experiments point out that its main contribution in vivo is Ser7 phosphorylation.[8] Several phosphorylation ambitions for CDK8 have been identified, along with the RNA polymerase II (RNAPII) C-terminal area (CTD) histone H3,2,3 subunits of

standard transcription elements (GTFs) and positive trans-activators, however how these phosphorylation occasions make a contribution to the common organic undertaking of CDK8 stays unwell defined. CDKs have been at first characterised by way of their function in legislation of the mobile cycle, countless participants of this household have direct features in legislation of RNAPII activity. The nice recognized of these 'transcriptional CDKs' (tCDKs) are CDK7, CDK8 and CDK9. CDK9 is the important Ser2 kinase, however it can additionally make a contribution to Ser5 phosphorylation each in vitro and in vivo.[9] CDK19 was once sporadically referred to as CDK11. Non-cell cycle CDKs, such as CDK5, are solely mentioned in the context of their interactions with interphase cyclins, such as cyclin E–CDK5 characteristic in post-mitotic neurons. Although each CDK8 and CDK19 companion with apparently equal Mediator complexes. The subsequent induction in S segment of cyclin A2, which companions with CDK2 and CDK1, and the activation of cyclin B1– CDK1 at the onset of mitosis, power the development of cells via the the rest of the cellphone cycle via the phosphorylation of a massive quantity of proteins that are concerned in DNA replication, as properly as in centrosome and chromosome functions. In assessment to yeast, the mammalian mobilephone cycle has advanced to encompass extra Cdks, such that the features of a single Cdk in yeast is now divided amongst various mammalian Cdks. Thus far, Cdk, cyclin and CKI household individuals have been implicated in transcription, DNA injury repair, proteolytic degradation, epigenetic regulation, metabolism, stem phone self-renewal, neuronal features and spermatogenesis. Accordingly, Cdks are perceived as the engine that drives phone cycle development whereas cyclins are regarded to be the gears that are modified to resource the transition between cycle phases.[10] The kinase exercise of Cdk/cyclin complexes is tightly regulated through a plethora of Cdk inhibitors (CKIs), which serve as brakes to halt cellphone cycle development beneath destructive conditions.[11]

## DIVERSE BIOLOGICAL FUNCTIONS OF CDK8

Among the many cell features of CDK8, the most extraordinary is its involvement in transcription. CDK8 is section of the Mediator complex, a massive multi-subunit protein complicated that is central to the law of transcription in eukaryotes.




***Fig2.Biological functions of CDK8***. *(I) Smad transactivation: C-terminal domain-phosphorylated R-Smads complicated with Smad4 and translocate to the nucleus. CDK8/CDK9-mediated phosphorylation of R-Smads at the linker region enhances the transactivation of TGFβ/BMP-regulated genes by facilitating their interaction with coactivators. This phosphorylation additionally results in turnover of R-Smads, closing down target organic phenomenon. (II) NOTCH signaling: Binding of a matter to NOTCH receptor induces chemical process cleavage to unleash NICD, that stimulates target organic phenomenon within the nucleus. CDK8 phosphorylates NICD, priming it for degradation and ultimately terminating*

*target organic phenomenon. (III) STAT1 signaling: Upon IFN-γ stimulation, JAK-phosphorylated STAT1 translocates to the nucleus. CDK8 phosphorylates STAT1 at Ser727 within the nucleus to control the expression of IFN-γ-dependent genes. (IV) β-Catenin pathway: Binding of Wnt supermolecule to a Frizzled family receptor activates tousled (Dsh) and later deactivates a destruction complicated that consists of GSK3β, AXIN, and APC. within the absence of Wnt communication, this destruction complicated phosphorylates β-catenin for degradation inside the living substance. within the presence of Wnt communication, β-catenin translocates to the nucleus to stimulate the transcription of TCF/LEF-dependent genes. CDK8 promotes β-catenin-dependent transcription by acting as a β-catenin coactivator and by phosphorylating E2F1, a β-catenin antagonist. (V) simple protein phosphorylation: CDK8-Mediator complicated phosphorylates Ser10 of simple protein H3, an occurrence related to the activation of organic phenomenon. (VI) Cell cycle: Skp2 promotes mH2A1 ubiquitination and CDK8 expression to control G2/M transition. (VII) HypoXia-induced genes: CDK8-Mediator complicated regulates the expression of hypoXia-induced genes via accomplishment of SEC. (VIII) Lipogenesis: CDK8 inhibits lipogenesis by phosphorylating SREBP-1C, priming it for degradation.*

CDK8 has been described as a coactivator in molecular pathways of biomedical relevance, inclusive of the β-catenin pathway the p53 pathway, the serum response network, the TGFβ signaling pathway as nicely as in thyroid hormone-dependent transcription. CDK8 ought to promote gene pastime at more than one ranges of the transcription cycle. CDK8 is a fine regulator of serum response gene expression. CDK8 positively influences RNAPII CTD phosphorylation at Ser5 and Ser2 besides an impact on whole RNAPII occupancy at FOS, EGR1, EGR2 and EGR3.[12-15]

**CDK8 is a Positive Regulator of p53-Dependent Transcription**

Early research in mammalian cells indicated recruitment of CDK8 alongside with core Mediator subunits to genes regulated by means of the aryl hydrocarbon receptor and serum response elements however the position of CDK8 in transcriptional activation at these areas used to be now not explored at the time.




***Fig.3Mediator as an end point of signalling cascades.****Four representative, streamlined signalling pathways are shown. Every pathway is triggered by utilizing various indicators; for example, wnt-β catenin signalling is triggered throughout enhance and differentiation; p53 is triggered throughout mobile pressure; toll-like receptors (tlrs) are triggered in response to infection and contamination, and sterol regulative detail-binding healthy protein 1 (srebp1) is triggered in reaction to metabolic hints. Each path transforms on an unique transcription element (tf) that targets a remarkable mediator subunit (mediator subunits that involve with particular tfs are shown in the similar colour), which helps with to hire and control mediator rate of passion at choose genomic loci. The quit outcome is tf-dependent activation (or suppression) of a chosen establish of genetics that are important for the reaction to the stimulation. Owing to mediator's function in communicating and incorporating those signs instantly to the transcription equipment (consisting of the rna polymerase ii (pol ii) enzyme itself), mediator can be taken into account an stop factor of signalling cascades152. Emergency room, endoplasmic reticulum; gsk3, glycogen synthase kinase three; irf7, interferon regulative point 7; myd88, myeloid differentiation 88; traf3, tumour necrosis provide receptor-related facet.*

Our lookup into the mechanism of rules of the p53 goal gene p21 (CDKN1A) led to a comparable statement of CDK8 recruitment upon activation, which brought about us to immediately check the have an effect on of CDK8 on gene activity.[16] In response to p53

activation through UV-mediated DNA damage, p21 undergoes restrained rounds of transcription observed by way of speedy inactivation and loss of pre-loaded RNAPII. In contrast, p53-activating retailers such as Nutlin-3 lead to sustained p21 activation over many hours barring loss of promoter-bound RNAPII. We observed that this unequal law of p21 is no longer decided with the aid of differential p53 binding or p53-mediated histone acetylation, however correlates as a substitute with the meeting of stimulus-specific transcriptional complexes at the promoter. Whereas positive core Mediator subunits are recruited to p21 regardless of the p53-activating agent, CDK8, Cyclin C and MED12 are recruited solely throughout prerequisites of sustained activation. Similarly, whilst binding of TBP and TFIIA happens in all scenarios, affiliation of TFIIB and TFIIF will increase solely beneath sustained promoter activity.[17-19] Such differential conduct amongst Mediator subunits and GTFs should be indicative of remnant scaffold complexes after transient activation versus 'complete' PIC assemblies maintained throughout stipulations of sustained re-initiation. CDK8 confirmed that CDK8 is ordinarily a nice regulator of transcription inside this community (Donner and Espinosa, unpublished results.[20]

**Phosphorylation of Transcription Factors**

CDK8 can adjust gene expression with the aid of phosphorylation of TFs which include moms in opposition to decapentaplegic homolog (Smad), neurogenic locus notch homolog protein (NOTCH), sign transducer and activator of transcription 1 (STAT1) and sterol regulatory element-binding protein 1C (SREBP-1C). Phosphorylation can at once have an effect on TF recreation or top them for ubiquitin-mediated degradation. CDK8 enhances the transactivation possible and turnover of receptor-regulated Smad proteins (R-Smads) in the bone morphogenetic protein (BMP)/transforming increase issue β (TGFβ) pathways.[21] The TGFβ household of cytokines are vital regulators of mobile phone cycle, differentiation, and apoptosis. Nucleoplasm CDK8/CDK9 phosphorylates RSmads at their linker regions, enabling the binding to coactivators that are required for environment friendly transcription of goal genes.[22] This phosphorylation additionally primes R-Smads for eventual degradation. Hence, CDK8/CDK9-mediated phosphorylation directs the transcriptional exercise and turnover of activated Smad proteins. CDK8 regulates the NOTCH signaling pathway, which is crucial for cell-to-cell communication, neuronal development, and T-cell differentiation. Binding of a ligand to the extracellular area of NOTCH receptors induces proteolytic cleavage to launch NOTCH intracellular area (NICD), which enters the mobile phone nucleus to prompt the transcription of NOTCH goal genes. CDK8 controls the characteristic of NICD with the aid of phosphorylation, ensuing in its ubiquitination and subsequent termination of goal gene

expression.[23] This termination is notion to be necessary in resetting goal genes for the subsequent spherical of NOTCH signaling activation and in setting up a NOTCH signaling gradient.[24]

**CDK8 Enhances Smad Transactivation by Enhancing Co-Activator Recruitment**

Activation of the membrane receptors for TGFβ and BMP leads to C-terminal phosphorylation of the receptor-regulated SMAD household of transcription elements (R-SMADs) and subsequent translocation to the nucleus the place they manipulate the expression of thousands of genes. Conversely, hostile signaling via stress- and mobile phone cycle-regulated kinases (MAPKs and CDK2/4, respectively) outcomes in phosphorylation of the R-SMADs in their linker area main to cytoplasmic retention and degradation. A latest record describes an extra layer of legislation of R-SMAD activity. Whereas antagonist-driven linker phosphorylation takes place in the cytoplasm, the Massague crew determined that TGFβ and BMP activation lead to linker phosphorylation in the nucleus with the aid of CDK8 and CDK9 (this tournament used to be dubbed agonist-induced linker phosphorylation or ALP). The practical outcome of ALP is twofold. First, ALP is fundamental for R-SMADs to entirely spark off their goal genes. Serine to alanine substitution of the ALP websites inside SMAD5 and SMAD3 attenuates their potential to spark off transcription, suggesting ALP may also be vital for interplay with coactivators. Indeed, ALP of SMAD1 used to be proven to be required for interplay with the coactivator protein YAP. Second, ALP primes activated R-SMADs for turnover via appearing as a binding website for unique E3 ubiquitin ligases such as Smurf1.[25] Accordingly, knockdown of both CDK8 or CDK9 led to slower degradation of activated R-SMADs following elimination of agonist. Thus, CDK8 and CDK9 couple the transactivation achievable of the R-SMADs with their turnover to make sure unique temporal manage of TGFβ- and BMP-responsive genes.[26]This function for CDK8 parallels that found for SRB10 in the galactose-induced transcriptional program, the place phosphorylation of Gal4 by means of SRB10 caused its degradation, which in flip was once required for full gene activation. Transactivation-coupled turnover has grow to be a recurrent theme in transcriptional regulation, and CDK8 might also play a extensive function in this phenomenon. Along these lines, the Jones lab mentioned that CDK8 is recruited by means of the coactivator Mastermind to Notch-responsive genes, the place it centered the Notch intracellular area for turnover.[27]

**CDK8 is required for assembly of elongation complexes**

In settlement with the reality that CDK8 performs no function in RNAPII recruitment, it is located that CDK8 depletion did now not have an effect on recruitment or activation of the key trans-activators performing at the FOS promoter.[28] The SRF–ELK1 complex is constitutively

certain to the chromatin of its goal genes and is activated through MAPK-dependent phosphorylation. Phosphorylation of the CTD of ELK1 has been proven to be vital for the allosteric stimulation of histone acetyltransferase (HAT) activities. CDK8 depletion did no longer have an effect on the tiers of chromatin-bound SRF or ELK1.[29] Likewise, no determined variations in ELK1 phosphorylation or usual histone acetylation (AcH4). As expected, CDK8 did no longer have an effect on the chromatin bound ranges of PIC elements worried in RNAPII recruitment, such as TBP or TFIIB.[30]

**CDK8 Regulates RNAPII Elongation without Affecting HIF1A Binding or Histone Acetylation**

CDK8 is a fine regulator of RNAPII endeavor at these HIF1A goal genes, in all likelihood appearing to promote RNAPII elongation.[31] Upon hypoxia, HIF1A hydroxylation is impaired, which leads to accelerated HIF1A degrees and more suitable affiliation of the HIF1A C-TAD with p300/CBP. Importantly, CDK8 depletion does no longer have an effect on HIF1A chromatin binding or histone acetylation. In fact, CDK8 knockdown leads to a modest enlarge in HIF1A binding and histone H4 acetylation at the STC2 locus. This demonstrates that HIF1A binding and the subsequent enlarge in histone acetylation are no longer enough to wholly set off RNAPII, for this reason revealing the existence of an additional, before unappreciated coactivation match involving CDK8 at these genes.[32-33]

**CDK8-Mediator Promotes RNAPII Elongation within the Serum Response Network**

Interestingly, whereas CDK8 was once required for β-catenin-dependent transformation, Firestein et al. suggested that overexpression of a dominant poor model of TCF had solely a partial impact on CDK8-induced transformation, suggesting that CDK8 performs extra oncogenic roles outdoor the Wnt pathway.[34] Given the outstanding function of Ras/MAPK-dependent signaling in tumorigenesis, we postulated that CDK8 should have features inside the MAPK-regulated transcriptional program.[35] Using isogenic mobile traces with ordinary or decreased stages of CDK8, we determined that CDK8 is certainly a amazing superb regulator of instant early genes (IEGs), these which are strongly and transiently brought about inside minutes of boom issue stimulation. ChIP evaluation confirmed that CDK8 is recruited to these genes for the duration of activation as phase of CDK8-Mediator. Remarkably, we located that CDK8 depletion did now not have an effect on recruitment of RNAPII to IEGs or average RNAPII intragenic occupancy, however alternatively precipitated a clear reduce in RNAPII CTD phosphorylation at each Ser2 and Ser5 at the genes examined barring affecting whole mobile degrees of both marks.[36] Nuclear run-on experiments proven that CDK8 depletion leads to the look of slower elongation complexes. Furthermore, biochemical fractionation showed

that P-TEFb co-purifies with the free CDK-module. In sum, these effects point out that Mediator, by way of CDK8, regulates post-RNAPII recruitment steps inside the serum response network. The thought that Mediator regulates elongations steps used to be first brought by way of the Berk lab. In their pioneering work, they recognized MED23 as the interface via which the serum-activated element ELK1 recruits Mediator, which include CDK8, to serum responsive genes. Although abolishing Mediator recruitment significantly impaired transcriptional activation, a substantial fraction of RNAPII remained certain to the promoter main them to conclude that Mediator affected each recruitment and post-recruitment steps. Although these efforts did now not check the function of CDK8 itself, it although installed the thinking that Mediator should promote late steps of the transcription cycle.[37-40]

**Pharmacological Inhibition and Knockdown of CDK8/ CDK19**

Studies have proven that the results of pharmacological inhibition of CDK8/CDK19 are wonderful from their gene knockdown. For example, whilst CDK8 knockdown suppressed the phosphorylation of E2 promoter binding component 1 (E2F1) at Ser375, CDK8/CDK19 inhibitor CCT251545 did no longer have an effect on this phosphorylation. Furthermore, CDK8/ CDK19 kinase inhibitors do no longer produce the equal phenotype as CDK8 knockdown.[41] For example, whilst CDK8 knockdown decreased the proliferation of HCT116 cells, CDK8/CDK19 inhibitors had little impact on these cells. Furthermore, the transcriptomic outcomes of CDK8 or CDK19 knockdown and their pharmacological inhibition in HCT116 have been additionally different. Taken together, these outcomes exhibit that the consequences of CDK8 and/or CDK19 knockdown are wonderful from these induced with the aid of inhibition of their kinase activities.[42] In fact, kinase-independent features of CDK8 and CDK19 have been documented in the literature.[43] CDK8 was once proven to stimulate the proliferation of melanoma cells in a kinase-independent manner, whilst CDK19 regulates p53 responses independently of its kinase activity.[44]

**CDK8 Kinase Activity Promotes Glycolysis**

CDK8 kinase undertaking has extra world Cell consequences on metabolism past 0glycolysis. Microarray facts for the depletion of both kinase and evaluation of expression information for human cancers endorse that CDK8 performs the dominant function in the expression of these genes, especially in sure cancer types, such as lung adenocarcinoma.[45-46] Therefore, tumors that overexpress CDK8 may also be extra probably to reply to aggregate remedies with inhibitors of CDK8/19 and glycolysis than tumors overexpressing CDK1.[47-48]

**CDK8 maintains embryonic stem cells in an undifferentiated state**

CDK8 in regulating each tumor and embryonic stem cellphone differentiation states via regulating MYC. We in addition become aware of a CDK8- regulated MYC signature that is particularly expressed in terrible prognosis colon tumors that are poorly differentiated.[49] Together these observations increase the opportunity that the stem cell– like homes of most cancers' cells may additionally be particularly inhibited by means of therapeutically concentrated on CDK8.[50]

**CLINICAL RELEVANCE OF CDK8**

CDK8 is concerned in quite a few key developmental and mobile pathways, and as a result it is unsurprising that dysregulation of CDK8 is regularly implicated in cancers.[51] Nonetheless, CDK8 seems to play context-specific roles in specific cancers whilst it acts as a promoter in many cancers, instances to the opposite are emerging. In CRC, CDK8 has been conferred an oncogene status. It is additionally overexpressed in melanoma, breast, prostate, and pancreatic cancers.[52] Inhibition of CDK8 through microRNA, small interfering RNA, or brief hairpin RNA (shRNA) suppressed the proliferation in melanoma, prostate, CRC, and breast cancers. Stimulatingly, CDK8 inhibition has been proven to increase the cytotoxicity of NK cells. Consequently, CDK8 represents a promising goal for therapeutic validation. This part small print the exceptional mechanisms via which CDK8 contributes to tumorigenesis and how pharmacological inhibition of CDK8 may want to be applicable to the remedy of such cancers.[53-54]

**BREAST CANCER**

Breast most cancers is the most frequent woman most cancers and the 2nd main purpose of most cancers dying in women. Approximately 70% of breast cancers categorical estrogen receptor alpha (ERα) and are termed ER-positive.[55] ERα, a member of the steroid hormone receptor family, mediates the organic consequences of estrogens functioning as a ligand-inducible transcription aspect that drives proliferation and survival of ER-positive breast most cancers cells. Transcription-regulating kinases CDK7, CDK9 and CDK8/19 have turn out to be actively pursued objectives in most cancers therapy, due in section to their outcomes on super-enhancers that boost for the duration of carcinogenesis and turn out to be necessary for the survival of tumor cells. A wide variety of organizations are growing inhibitors of CDK8/19 Mediator kinase, which exhibit severa consequences on oncogenic transcriptional signaling and potentiate the consequences of chemotherapeutic tablets through blocking off drug-induced transcriptional activation of proteins related with drug resistance and tumor progression.[56-57] As single agents, however, CDK8/19 kinase inhibitors confirmed little or no growth-inhibitory impact in the majority of examined tumor and everyday cellphone types.

While the linkage of CDK8 to carcinogenesis was once initially found in colon cancer, CDK8/19 kinase inhibitors did now not inhibit the increase of CDK8-overexpressing colon most cancers cells. The first proof for single-agent pastime of CDK8/19 inhibitors was once said for a subset of leukemia cellphone lines, the place CDK8/19 inhibition had a robust anti-proliferative impact via hyper-activating super-enhancer-associated genes in such leukemias. We and others have before proven that CDK8/19 is a bad prognostic marker in breast cancer. In the current study, we have determined that CDK8 inhibition additionally inhibits ER signaling and suppresses the boom of ER-positive breast most cancers cells, the most frequent kind of breast cancer, in vitro and in vivo.[58-60]

**PROSTATE CANCER**

Prostate most cancers is the 2d most often identified most cancers and sixth main motive of cancerassociated loss of life in males.84 Although being healing in the early stages, few cure picks are presently accessible for advanced-stage disease.[61] Cluster evaluation of TCGA expression statistics segregated tumor entities, indicating tumor-type–specific Mediator complicated compositions.Only prostate most cancers was once marked through excessive expression of CDK19. In important prostate cancer, CDK19 used to be related with multiplied aggressiveness and shorter disease-free survival.[62] During most cancers progression, best stages of CDK19 and of its paralog CDK8 have been existing in metastases. In vitro, inhibition of CDK19 and CDK8 via knockdown or therapy with a selective CDK8/CDK19 inhibitor appreciably diminished migration and invasion.[63]

**MELANOMA**

In spite of being the least frequent and being curable if detected early, melanoma debts for the majority of pores and skin most cancers deaths.[64] CDK8 has been implicated in melanoma-genesis, the place it has been proven to be regulated by means of the histone variant mH2A and drives proliferation in a kinase-independent manner.[65] Loss of mH2A isoforms positively correlated with melanoma malignancy, and useful research indicated that this loss drives melanoma development thru direct transcriptional upregulation of CDK8.[66] This find out about has essential implications for therapeutic strategies relying on sellers that inhibit CDK8 kinase pastime as the kinase-independent features may additionally provide choice routes for the survival of most cancers cells.[67]

**COLORECTAL CANCER**

CRC is the 0.33 most frequent kind of most cancers and fifth in phrases of cancer-associated deaths, accounting for 694 zero deaths and 1.36 million new instances each year. CRC arises

in colon epithelial cells as a end result of accrued genetic and epigenetic changes. The most regularly occurring genetic alteration is the deactivation of the APC tumor suppressor gene, main to aberrant activation of the Wnt signaling pathway.[68] This aberrance consequences in the stabilization and nuclear translocation of β-catenin, which binds to T-cell component (TCF) and enhances the transactivation of genes (e.g., MYC, AXIN2, and LEF1) that are implicated in CRC. The therapeutic fee of concentrated on CDK8 began with the record through Hahn and co-workers that proposed CDK8 as an oncogene in CRC. CDK8 was once proven to be overexpressed in 60% of CRC and that CDK8 knockdown decreased the proliferation in CRC cells and xenograft fashions harboring CDK8 amplification. Furthermore, the kinase pastime of CDK8 was once required for each transcription of β-catenin goal genes and proliferation of CRC cells.[69] CDK8 was once later recognized to repress E2F1, a poor regulator of β-catenin/TCF based transcription, with the aid of phosphorylating it at Ser375. Thus, CDK8 promotes CRC by means of facilitating the transcription of β-catenin goal genes and suppressing E2F1.[70] CDK8 has additionally been suggested to be required to keep CRC cells in an undifferentiated state. Adler et al. printed that loss of CDK8 promoted differentiation and inhibited tumor boom in CRC xenograft models. In addition, CDK8 has been proven to play a fundamental function in permitting most cancers cells to use glucose as an power source.[71] Cancer cells regularly showcase upregulated glycolysis to meet the excessive demand for proliferation and survival even below cardio conditions, a phenomenon regarded as Warburg effect.[72] HCT116 cells engineered to raise a kinase-dead CDK8 (CDK8as/as) decreased glucose transporter (GLUT3) expression and glucose import, as nicely as mobilephone proliferation and anchorage unbiased boom in normoxia and hypoxia. Inhibition of CDK8 brought about downregulation of countless genes, e.g., SLC2A3, HK1, and ENO1, that are worried in the glycolytic cascade and sensitized HCT116 cells to glycolysis inhibitor 2-deoxy-Dglucose (2DG). These consequences have been additionally reproduced with a CDK8/CDK19 inhibitor, senexin A as upregulation of glycolysis is a frequent characteristic of cancer, CDK8 inhibitor and its mixture with tablets that block glycolysis may additionally allow unique concentrated on of most cancers cells barring damaging consequences on regular cells.[73] The oncogenic function of CDK8 in CRC was once in addition validated by means of two cohort research of CRC cases. Among 372 colon most cancers patients, the 5-year survival charge was once appreciably decrease in affiliation with greater expression degree of CDK8. However, this was once now not the case in rectal cancer, the place no correlation between CDK8 and the normal mortality price was once observed. Another learn about attested that in CRC, degrees of CDK8 positively correlated with stage of the disease. Its overexpression was

once greater in tiers III and IV than in stage I, elevating the opportunity that CDK8 should be concerned in the transformation of colorectal adenoma to carcinoma. While considerable information assist the function of CDK8 as an oncogene, different work has raised the opportunity of its opposite function. McCleland et al. stated that deletion of CDK8 in APCMin intestinal tumor mannequin shortened the survival and accelerated tumor burden in contrast to CDK8 wild-type mice. In human CRC, mutation in Wnt-β-catenin signaling is one of the earliest activities of tumorigenesis and progression. Additional mutations, such as CDK8 amplification, would accumulate over time, supplying selective benefit for tumor boom or metastasis. However, in the ApcMin mice, CDK8 is deleted prior to tumor initiation; in the absence of CDK8, the tumors may also take advantage of choice and extra aggressive transcriptional and signaling pathways for growth. Further studies, for example, using transgenic CDK8 overexpression, would be treasured to examine pro-oncogenic position of CDK8. Hematological Malignancies. Studies with CDK8/ CDK19 inhibitors, i.e., 1 and SEL120-34A have centered on the inhibition of CDK8/CDK19 kinase pastime in AML. CDK8 and CDK19 had been recognized as bad regulators of super-enhancer (SE)-associated genes in AML. Inhibition of CDK8/CDK19 by using compound 1 led to sturdy antileukemic exercise in AML cells by means of a mechanism involving upregulation of SE-associated genes with tumor suppressing and lineage-controlling functions. On the different hand, compound two inhibited the boom of AML cells with excessive tiers of phosphorylated STAT1-Ser727 and STAT5-Ser726. The in vitro effectiveness of the two compounds has additionally translated to anticancer efficacy in AML xenograft models. These promising preclinical facts bought from two structurally awesome compounds propose future improvement of CDK8/ CDK19 inhibitors for AML therapy. [74-79]

**Cyclin-dependent kinase 8 mediates chemotherapy induced tumor-promoting paracrine activities**

Chemotherapy and radiation remedy now not solely kill tumor cells however additionally result in tumor-promoting paracrine things to do in the tumor environment, which might also limit cure efficacy and make contributions to de novo carcinogenesis. These paracrine results consist of the promoting of tumor formation, stimulation of angiogenesis, metastasis, tumor resistance to chemotherapy, and secretion of a couple of tumor-promoting cytokines in vivo and in vitro. CDK8 has been recognized as an oncogene amplified in ∼50% of colon cancers the place it potentiates Wnt/β-catenin, and as a melanoma oncogene related with the loss of a histone variant macroH2A. CDK8 has additionally been implicated in Notch signaling and Smad activation in BMP and TGF-β pathways. CDK8 used to be proven to potentiate transcriptional

consequences of p53, such as p21 induction. However, the consequences of CDK8 inhibition determined in the existing find out about took place downstream of p21 and have been now not due to diminished p21 induction. [80]

**References**

1. Philip S, Kumarasiri M, Teo T, Yu M, Wang S. Cyclin-dependent kinase 8: A new hope intargeted cancer therapy? Miniperspective. Journal of medicinal chemistry. 2017 Dec 21;61(12):5073-92.
2. Tsafrir D, Bacolod M, Selvanayagam Z, Tsafrir I, Shia J, Zeng Z, Liu H, Krier C, Stengel RF, Barany F, Gerald WL. Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer research. 2006 Feb 15;66(4):2129-37.
3. Choudhary ML, Sisodiya SS, Kumar N, Mishra SS. Cyclin dependent kinases: old target with new challenges for anti-cancer drugs. Int J Cancer Res. 2022;12(2):109-21.
4. Galbraith MD, Donner AJ, Espinosa JM. CDK8: a positive regulator of transcription. Transcription. 2010 Jul 1;1(1):4-12.
5. Lecl0erc V, Tassan JP, O'farrell PH, Nigg EA, Leopold P. Drosophila Cdk8, a kinase partner of cyclin C that interacts with the large subunit of RNA polymerase II. Molecular biology of the cell. 1996 Apr;7(4):505-13.
6. Tassan JP, Jaquenoud M, Leopold P, Schultz SJ, Nigg EA. Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C. Proceedings of the National Academy of Sciences. 1995 Sep 12;92(19):8871-5.
7. Espinosa JM, Donner AJ, Galbraith M, Taatjes D, Ebmeier C. CDK8 is a positive regulator of transcriptional elongation within the serum response network. The FASEB Journal. 2010 Apr; 24:456-5.
8. Galbraith MD, Allen MA, Bensard CL, Wang X, Schwinn MK, Qin B, Long HW, Daniels DL, Hahn WC, Dowell RD, Espinosa JM. HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. Cell. 2013 Jun 6;153(6):1327-39.
9. Sharko AC, Lim CU, McDermott MS, Hennes C, Philavong KP, Aiken T, Tatarskiy VV, Roninson IB, Broude EV. The inhibition of CDK8/19 mediator kinases prevents the development of resistance to EGFR-targeting drugs. Cells. 2021 Jan 12;10(1):144.
10. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG. CDK8 is a colorectal cancer oncogene that regulates β-catenin activity. Nature. 2008 Sep;455(7212):547-51.
11. Bancerek J, Poss ZC, Steinparzer I, Sedlyarov V, Pfaffenwimmer T, Mikulic I, Dölken L, Strobl B, Müller M, Taatjes DJ, Kovarik P. CDK8 kinase phosphorylates transcription factor

STAT1 to selectively regulate the interferon response. Immunity. 2013 Feb 21;38(2):250-62.

12. Wu D, Zhang Z, Chen X, Yan Y, Liu X. Angel or Devil?-CDK8 as the new drug target. European Journal of Medicinal Chemistry. 2021 Mar 5;213:113043.
13. Loyer P, Trembley JH, Katona R, Kidd VJ, Lahti JM. Role of CDK/cyclin complexes in transcription and RNA splicing. Cellular signalling. 2005 Sep 1;17(9):1033-51.
14. Straub J, Venigalla S, Newman JJ. Mediator's Kinase Module: a modular regulator of cell fate. Stem Cells and Development. 2020 Dec 15;29(24):1535-51.
15. Poss ZC, Ebmeier CC, Taatjes DJ. The Mediator complex and transcription regulation. Critical reviews in biochemistry and molecular biology. 2013 Nov 1;48(6):575-608.
16. Donner AJ, Szostek S, Hoover JM, Espinosa JM. CDK8 is a stimulus-specific positive coregulator of p53 target genes. Molecular cell. 2007 Jul 6;27(1):121-33.
17. Galbraith MD, Donner AJ, Espinosa JM. CDK8: a positive regulator of transcription. Transcription. 2010 Jul 1;1(1):4-12.
18. Nemet J, Jelicic B, Rubelj I, Sopta M. The two faces of Cdk8, a positive/negative regulator of transcription. Biochimie. 2014 Feb 1;97:22-7.
19. Szilagyi Z, Gustafsson CM. Emerging roles of Cdk8 in cell cycle control. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms. 2013 Sep 1;1829(9):916-20.
20. Philip S, Kumarasiri M, Teo T, Yu M, Wang S. Cyclin-dependent kinase 8: A new hope in targeted cancer therapy? Miniperspective. Journal of medicinal chemistry. 2017 Dec 21;61(12):5073-92.
21. Nemet J, Jelicic B, Rubelj I, Sopta M. The two faces of Cdk8, a positive/negative regulator of transcription. Biochimie. 2014 Feb 1;97:22-7.
22. Nelson C, Goto S, Lund K, Hung W, Sadowski I. Srb10/Cdk8 regulates yeast filamentous growth by phosphorylating the transcription factor Ste12. Nature. 2003 Jan;421(6919):187-90.
23. Galbraith MD, Donner AJ, Espinosa JM. CDK8: a positive regulator of transcription. Transcription. 2010 Jul 1;1(1):4-12.
24. Putz EM, Gotthardt D, Hoermann G, Csiszar A, Wirth S, Berger A, Straka E, Rigler D, Wallner B, Jamieson AM, Pickl WF. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell reports. 2013 Aug 15;4(3):437-44.
25. Taatjes DJ, Marr MT, Tjian R. Regulatory diversity among metazoan co-activator complexes. Nature Reviews Molecular Cell Biology. 2004 May;5(5):403-10.

26. Wu D, Zhang Z, Chen X, Yan Y, Liu X. Angel or Devil?-CDK8 as the new drug target. European Journal of Medicinal Chemistry. 2021 Mar 5;213:113043.
27. Sundqvist A, Ten Dijke P, van Dam H. Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity. Breast Cancer Research. 2012 Feb;14(1):1-3.
28. Donner AJ, Ebmeier CC, Taatjes DJ, Espinosa JM. CDK8 is a positive regulator of transcriptional elongation within the serum response network. Nature structural & molecular biology. 2010 Feb;17(2):194-201.
29. Galbraith MD, Allen MA, Bensard CL, Wang X, Schwinn MK, Qin B, Long HW, Daniels DL, Hahn WC, Dowell RD, Espinosa JM. HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. Cell. 2013 Jun 6;153(6):1327-39.
30. Menzl I, Witalisz-Siepracka A, Sexl V. CDK8-novel therapeutic opportunities. Pharmaceuticals. 2019 Jun 19;12(2):92.
31. Galbraith MD, Allen MA, Bensard CL, Wang X, Schwinn MK, Qin B, Long HW, Daniels DL, Hahn WC, Dowell RD, Espinosa JM. HIF1A employs CDK8-mediator to stimulate RNAPII elongation in response to hypoxia. Cell. 2013 Jun 6;153(6):1327-39.
32. Perez-Perri JI, Dengler VL, Audetat KA, Pandey A, Bonner EA, Urh M, Mendez J, Daniels DL, Wappner P, Galbraith MD, Espinosa JM. The TIP60 complex is a conserved coactivator of HIF1A. Cell reports. 2016 Jun 28;16(1):37-47.
33. Chen M, Liang J, Ji H, Yang Z, Altilia S, Hu B, Schronce A, McDermott MS, Schools GP, Lim CU, Oliver D. CDK8/19 Mediator kinases potentiate induction of transcription by NFκB. Proceedings of the National Academy of Sciences. 2017 Sep 19;114(38):10208-13.
34. Fant CB, Taatjes DJ. Regulatory functions of the Mediator kinases CDK8 and CDK19. Transcription. 2019 Mar 15;10(2):76-90.
35. McDermott MS, Chumanevich AA, Lim CU, Liang J, Chen M, Altilia S, Oliver D, Rae JM, Shtutman M, Kiaris H, Győrffy B. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget. 2017 Feb 21;8(8):12558.
36. Knuesel MT, Meyer KD, Donner AJ, Espinosa JM, Taatjes DJ. The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of mediator. Molecular and cellular biology. 2009 Feb 1;29(3):650-61.
37. Akoulitchev S, Chuikov S, Reinberg D. TFIIH is negatively regulated by cdk8-containing mediator complexes. Nature. 2000 Sep;407(6800):102-6.

38. Furumoto T, Tanaka A, Ito M, Malik S, Hirose Y, Hanaoka F, Ohkuma Y. A kinase subunit of the human mediator complex, CDK8, positively regulates transcriptional activation. Genes to Cells. 2007 Jan;12(1):119-32.
39. Liu Y, Kung C, Fishburn J, Ansari AZ, Shokat KM, Hahn S. Two cyclin-dependent kinases promote RNA polymerase II transcription and formation of the scaffold complex. Molecular and cellular biology. 2004 Feb 15;24(4):1721-35.
40. Yudkovsky N, Ranish JA, Hahn S. A transcription reinitiation intermediate that is stabilized by activator. Nature. 2000 Nov;408(6809):225-9.
41. Koehler MF, Bergeron P, Blackwood EM, Bowman K, Clark KR, Firestein R, Kiefer JR, Maskos K, McCleland ML, Orren L, Salphati L. Development of a potent, specific CDK8 kinase inhibitor which phenocopies CDK8/19 knockout cells. ACS medicinal chemistry letters. 2016 Mar 10;7(3):223-8.
42. Akamatsu M, Mikami N, Ohkura N, Kawakami R, Kitagawa Y, Sugimoto A, Hirota K, Nakamura N, Ujihara S, Kurosaki T, Hamaguchi H. Conversion of antigen-specific effector/memory T cells into Foxp3-expressing Treg cells by inhibition of CDK8/19. Science Immunology. 2019 Oct 25;4(40):eaaw2707.
43. Serrao A, Jenkins LM, Chumanevich AA, Horst B, Liang J, Gatza ML, Lee NY, Roninson IB, Broude EV, Mythreye K. Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer. Oncogene. 2018 Aug;37(35):4792-808.
44. Chen M, Li J, Liang J, Thompson ZS, Kathrein K, Broude EV, Roninson IB. Systemic toxicity reported for CDK8/19 inhibitors CCT251921 and MSC2530818 is not due to target inhibition. Cells. 2019 Nov 9;8(11):1413.
45. Galbraith MD, Andrysik Z, Pandey A, Hoh M, Bonner EA, Hill AA, Sullivan KD, Espinosa JM. CDK8 kinase activity promotes glycolysis. Cell reports. 2017 Nov 7;21(6):1495-506.
46. Dannappel MV, Sooraj D, Loh JJ, Firestein R. Molecular and in vivo functions of the CDK8 and CDK19 kinase modules. Frontiers in cell and developmental biology. 2019 Jan 14;6:171.
47. Näär AM, Taatjes DJ, Zhai W, Nogales E, Tjian R. Human CRSP interacts with RNA polymerase II CTD and adopts a specific CTD-bound conformation. Genes & development. 2002 Jun 1;16(11):1339-44.
48. Fryer CJ, White JB, Jones KA. Mastermind recruits CycC: CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Molecular cell. 2004 Nov 19;16(4):509-20.

49. Zhao X, Feng D, Wang Q, Abdulla A, Xie XJ, Zhou J, Sun Y, Yang ES, Liu LP, Vaitheesvaran B, Bridges L. Regulation of lipogenesis by cyclin-dependent kinase 8–mediated control of SREBP-1. The Journal of clinical investigation. 2012 Jul 2;122(7):2417-27.
50. Macias MJ, Martin-Malpartida P, Massagué J. Structural determinants of Smad function in TGF-β signaling. Trends in biochemical sciences. 2015 Jun 1;40(6):296-308.
51. Ohtsuka M, Ling H, Ivan C, Pichler M, Matsushita D, Goblirsch M, Stiegelbauer V, Shigeyasu K, Zhang X, Chen M, Vidhu F. H19 noncoding RNA, an independent prognostic factor, regulates essential Rb-E2F and CDK8-β-catenin signaling in colorectal cancer. EBioMedicine. 2016 Nov 1;13:113-24.
52. Schneider EV, Böttcher J, Blaesse M, Neumann L, Huber R, Maskos K. The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder. Journal of molecular biology. 2011 Sep 16;412(2):251-66.
53. Lloyd RL, Urban V, Muñoz-Martínez F, Ayestaran I, Thomas JC, de Renty C, O'Connor MJ, Forment JV, Galanty Y, Jackson SP. Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress. Nucleic acids research. 2021 Sep 7;49(15):8665-83.
54. Serrao A, Jenkins LM, Chumanevich AA, Horst B, Liang J, Gatza ML, Lee NY, Roninson IB, Broude EV, Mythreye K. Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer. Oncogene. 2018 Aug;37(35):4792-808.
55. Cowin P, Rowlands TM, Hatsell SJ. Cadherins and catenins in breast cancer. Current opinion in cell biology. 2005 Oct 1;17(5):499-508.
56. Sutherland RL, Musgrove EA. Cyclins and breast cancer. Journal of mammary gland biology and neoplasia. 2004 Jan;9(1):95-104.
57. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. Jama. 2005 Mar 9;293(10):1245-56.
58. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, Shi W, Jiang J, Yao PP, Zhu HP. Risk factors and preventions of breast cancer. International journal of biological sciences. 2017;13(11):1387.
59. Arribas J, Baselga J, Pedersen K, Parra-Palau JL. p95HER2 and breast cancer. Cancer research. 2011 Mar 1;71(5):1515-9.
60. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. The lancet oncology. 2001 Mar 1;2(3):133-40.

61. Pienta KJ, Esper PS. Risk factors for prostate cancer. Annals of internal medicine. 1993 May 15;118(10):793-803.
62. Rawla P. Epidemiology of prostate cancer. World journal of oncology. 2019 Apr;10(2):63.
63. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane database of systematic reviews. 2013(1).
64. Miller AJ, Mihm Jr MC. Melanoma. New England Journal of Medicine. 2006 Jul 6;355(1):51-65.
65. Schadendorf D, van Akkooi AC, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S. Melanoma. The Lancet. 2018 Sep 15;392(10151):971-84.
66. Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob JJ, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A, Roesch A. Melanoma. Nature reviews Disease primers. 2015 Apr 23;1(1):1-20.
67. Coit DG, Andtbacka R, Bichakjian CK, Dilawari RA, DiMaio D, Guild V, Halpern AC, Hodi FS, Kashani-Sabet M, Lange JR, Lind A. Melanoma. Journal of the National Comprehensive Cancer Network. 2009 Mar 1;7(3):250-75.
68. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA: a cancer journal for clinicians. 2009 Nov;59(6):366-78.
69. Iacopetta B. Are there two sides to colorectal cancer?. International journal of cancer. 2002 Oct 10;101(5):403-8.
70. Mármol I, Sánchez-de-Diego C, PradillaDieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. International journal of molecular sciences. 2017 Jan 19;18(1):197.
71. Eddy DM. Screening for colorectal cancer. Annals of Internal Medicine. 1990 Sep 1;113(5):373-84.
72. Fearon ER. Molecular genetics of colorectal cancer. Annual Review of Pathology: Mechanisms of Disease. 2011 Feb 28;6:479-507.
73. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. New England journal of medicine. 2005 Feb 3;352(5):476-87.
74. Potter JD. Colorectal cancer: molecules and populations. Journal of the National Cancer Institute. 1999 Jun 2;91(11):916-32.
75. Marley AR, Nan H. Epidemiology of colorectal cancer. International journal of molecular epidemiology and genetics. 2016;7(3):105.
76. Boyle P, Leon ME. Epidemiology of colorectal cancer. British medical bulletin. 2002 Dec 1;64(1):1-25.

77. Saif MW, Chu E. Biology of colorectal cancer. The Cancer Journal. 2010 May 1;16(3):196-201.
78. Haraldsdottir S, Einarsdottir HM, Smaradottir A, Gunnlaugsson A, Halfdanarson TR. Colorectal cancer-review. Laeknabladid. 2014 Feb 1;100(2):75-82.
79. Lieberman DA. Screening for colorectal cancer. New England Journal of Medicine. 2009 Sep 17;361(12):1179-87.
80. Porter DC, Farmaki E, Altilia S, Schools GP, West DK, Chen M, Chang BD, Puzyrev AT, Lim CU, Rokow-Kittell R, Friedhoff LT. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proceedings of the National Academy of Sciences. 2012 Aug 21;109(34):13799-804.